Director of Clinical Research; Associate Director for Cancer Networks
Mark Mishra, MD, is an Associate Professor of Radiation Oncology at the University of Maryland School of Medicine who focuses on treatment of patients with tumors of the central nervous system and genitourinary tract, as well as breast cancer. He serves as the Director of Clinical Research for the Department of Radiation Oncology, as Vice-Chair of the Greenebaum Comprehensive Cancer Center’s Clinical Research Committee, and as Chair of Radiation Oncology Executive Academic and Advisory Council.
He is a graduate of the University of Cincinnati College of Medicine and completed his residency in Radiation Oncology at Thomas Jefferson University, where he served as chief resident. He completed a clinical research fellowship in the NIH Clinical Research Training Program and also completed the Program in Clinical Effectiveness at the Harvard T.H. Chan School of Public Health. As Director of Radiation Oncology Clinical Research, Dr. Mishra oversees all clinical trial activities for Radiation Oncology at UMGCCC and at affiliated practices across the state of Maryland. He serves as the UMGCCC Voting-Member Contact PI for NRG Oncology.
Dr. Mishra’s research focus is centered on evaluating the comparative- and cost-effectiveness of new and complex radiation technologies, such as proton beam therapy, as well as evaluating novel uses of radiation therapy alone or in combination with other therapies. He has received the American Society of Radiation Oncology (ASTRO) Comparative Effectiveness Grant and is the Comparative Effectiveness Co-Chair for 2 recently activated national phase III studies (NRG BN009 and NRG CC009) focused on identifying new treatment approaches for brain metastases. Dr. Mishra is also the PI for 2 investigator-initiated trials at UMGCCC evaluating the efficacy of combining laser interstitial thermal therapy with radiation for patients with a recurrent glioma as well as patients with a newly diagnosed unresectable glioma.
As a result of his clinical trial work at UMGCCC he has been named as a recipient of the National Cancer Institute Cancer Center Investigator Team Leadership Award. His research has been supported by NIH, the Patient Centered Outcomes Research Institute (PCORI), ASTRO, and the Keep Punching Foundation. He has served as a member of the PCORI Patient Engagement Advisory Panel and on national level committees for ASTRO, the American College of Radiology, and the American Board of Radiology. His research has resulted in more than 75 peer-reviewed publications with more than 1,100 citations to date. He has also been recognized as a ‘Top Doctor’ by Baltimore Magazine.
Mishra MV, Bennett M, Vincent A, Lee OT, Lallas CD, Trabulsi EJ, Gomella LG, Dicker AP, Showalter TN. Identifying barriers to patient acceptance of active surveillance: content analysis of online patient communications. PLoS One. 2013 Sep 11
Mishra MV, Showalter TN. Pushing the limits of radiation therapy for prostate cancer: where do we go next? Semin Oncol. 2013 Jun; 40(3):297-307
Mishra MV, Showalter TN, Dicker AP. Biomarkers of Aging and Radiation Therapy Tailored to the Elderly: Future of the Field. Seminars in Radiation Oncology. 2012 Oct;22(4):334-8
Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. Cancer. 2016;122(10):1483-1501
Mishra MV, Andrews DW, Glass J, Evans JJ, Dicker AP, Shen X, Lawrence YR. Characterization and outcomes of optic nerve gliomas: a population-based analysis. Journal of Neuro-Oncology , 2012 May;107(3):591-7
Mishra MV, Shen X, Den RB, Champ CE, Trabulsi EJ, Lallas C, Gomella LG, Dicker AP, Showalter TN. Patterns of care for elderly men with low-risk prostate cancer: A population-based analysis. American Journal of Clinical Oncology. 2012 Aug 13
Mishra MV, Champ CE, Keith SW, Showalter TN, Anne PR, Bar-Ad V. Conditional survival probabilities in patients with resected pancreatic carcinoma: A population-based analysis. American Journal of Clinical Oncology. 2013 Mar 26
Lawrence YR, Mishra MV, Werner-Wasik M, Andrews DW, Showalter TN, Glass J, Shen X, Symon Z, Dicker AP. Improving prognosis of glioblastoma in the 21st century: Who has benefited most? Cancer, 2012 Sep 1;118(17):4228-34
Showalter TN, Mishra MV, Bridges JF. Factors that influence patient preferences for prostate cancer management options: A systematic review. Patient preference and adherence. 2015;9:899-911
Champ CE, Mishra MV, Ohri N, Showalter TN, Dicker AP, Simone NL. Dietary Recommendations during Cancer Treatment: Consistently Inconsistent? Nutrition and Cancer. 2013;18(1):97-103
Den RB, Feng F, Showalter TN, Mishra MV, Trabusli EJ, Lallas CD, Gomella LG, Kelly WK, Biirbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, Knudsen KE, Dicker AP. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after post-operatiave radiation therapy. International Journal of Radiation Oncology, Biology, Physics.
Nguyen TK, Goodman CD, Boldt RG, Warner A, Palma DA, Rodrigues GB, Lock MI, Mishra MV, Zaric GS, Louie AV. Evaluation of Health Economics in Radiation Oncology: A Systematic Review. International journal of radiation oncology, biology, physics. 2016;94(5):1006-1014